In this Bioanalysis Zone interview, Pegah Jalili (MilliporeSigma) discusses her current work in analytical R&D of biotherapeutic characterization and quantification, and what she thinks the future looks like for this field of bioanalysis.
Bioanalytical workflow for novel scaffold protein–drug conjugates: quantitation of total Centyrin protein, conjugated Centyrin and free payload for Centyrin–drug conjugate in plasma and tissue samples using liquid chromatography–tandem mass spectrometry
Alternative scaffold proteins have emerged as novel platforms for development of therapeutic applications. One such application is in protein–drug conjugates, which are analogous to antibody–drug conjugates. Find out more in this research article from Bioanalysis.
Webinar available to view on demand. Exploring the challenges a lack of industry standardization presents for CRO project managers and scientists as well as biopharma and biotech companies.
Webinar available to view on demand. The application of differential mobility spectrometry to overcome selectivity and sensitivity challenges for both small and large molecule quantitation in bioanalysis.
Developing bioanalytical LC–MS/MS methods for biotherapeutics and biomarkers: an interview with William Mylott
In this expert interview, William Mylott discusses developing bioanalytical LC–MS/MS methods for biotherapeutics and biomarkers.
The future of individualized medicine: intensified decentralized biotherapeutic production in combination with state-of-the-art diagnostics of the next generation
In this editorial the future of individualized medicine is reviewed, focusing on the decentralization of biotherapeutic production in combination with state-of-the-art diagnostics of the next generation.
In this interview, Jun Qu (University at Buffalo; NY, USA) describes his current research focuses, including the technologies he is currently developing. Jun goes on to discuss the challenges involved in implementing sensitive quantifications of biotherapeutics using LC–MS and speculates on the future of the technology.
Issue 23 of Bioanalysis volume 9 is now available, including an editorial discussing the matrix effects, a methodology on assay signaling and a White Paper on the rise of hybrid LBA/LCMS immunogenicity assays.
Take a look inside Bio-Rad’s custom recombinant antibody facility. Learn from our antibody experts how…
In this interview Mohsen Rajabi (FDA) discusses the process of FDA approval, why immunogenicity assays are so important and what he believes the future may hold for immunogenicity testing.